CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 37 enrolled
Drug / intervention
500 IR house dust mites allergen extract tablet +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01919554
NCT01919554Phase 1Completed
CompareCT.gov

Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis

Stallergenes Greer·interventional·Posted Aug 9, 2013·Updated Jan 17, 2025

In Brief

A Phase 1 clinical trial evaluating 500 IR house dust mites allergen extract tablet, 1000 IR house dust mites allergen extract tablet, and 2 other interventions for Allergic Rhinitis Due to House Dust Mite. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis Due to House Dust Mite
CountriesCanada
CollaboratorsSyneos Health

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.9 years ago

Interventions

500 IR house dust mites allergen extract tabletbiological

One sublingual tablet daily during 10 days

1000 IR house dust mites allergen extract tabletbiological

Two sublingual tablets daily during 10 days

1500 IR house dust mites allergen extract tabletbiological

Three sublingual tablets daily during 10 days

Placebo tabletbiological

One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets